Covered recipient · General Payments record
IMAD M OBEID
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
General Payments · PY2019–2025
$1,106.23
- Reported across 37 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $295.93 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $87.60 | 5 |
| Insmed, Inc. | $38.42 | 2 |
| GENZYME CORPORATION | $35.77 | 2 |
| Grifols USA, LLC | $29.58 | 1 |
| Pulmonx Corporation | $24.36 | 1 |
| Amgen Inc. | $24.08 | 1 |
| ANI Pharmaceuticals, Inc. | $24.05 | 1 |
| Acerta Pharma LLC | $16.84 | 1 |
| Respicardia, Inc. | $15.23 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $24.08 | 08/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228482103 | CMS |
| ANI Pharmaceuticals, Inc. | $24.05 | 11/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1248585192 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.84 | 11/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1206827447 | CMS |
| GENZYME CORPORATION | $17.80 | 10/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233689726 | CMS |
| GENZYME CORPORATION | $17.97 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233689738 | CMS |
| GlaxoSmithKline, LLC. | $20.27 | 07/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191691268 | CMS |
| GlaxoSmithKline, LLC. | $15.81 | 07/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191709752 | CMS |
| GlaxoSmithKline, LLC. | $14.40 | 08/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190859632 | CMS |
| GlaxoSmithKline, LLC. | $18.52 | 08/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190335401 | CMS |
| GlaxoSmithKline, LLC. | $18.60 | 12/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191669483 | CMS |
| Grifols USA, LLC | $29.58 | 12/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249599116 | CMS |
| Insmed, Inc. | $22.81 | 08/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186317685 | CMS |
| Insmed, Inc. | $15.61 | 09/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186273548 | CMS |
| Pulmonx Corporation | $24.36 | 07/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1199545503 | CMS |
| ZOLL Respicardia, Inc. | $15.23 | 08/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1237522925 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.